The gains came against a backdrop of falling net profits and cash reserves that will test Karolinska Development as it looks ahead to convertible debt obligations.
Karolinska Development, the investment arm of Karolinska Institute, witnessed a one-third annual increase in its portfolio value to SKr952m ($107.3m at December 31) in 2018 as it contemplated mixed operational fortunes at its biotech holdings.
Karolinska Development’s net profit fell year-on-year in both annual terms and during the fourth quarter, sliding by 83% and 53.4% respectively to $3.4m for the year and $1.7m for the quarter.
The firm invested a total of $14.1m in its portfolio companies in…
